Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

07.11.2023 - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of ...

Related Keywords

Denmark ,Cambridge ,Cambridgeshire ,United Kingdom ,Italy ,Bedford ,Massachusetts ,United States ,American , ,Augmentation Of Nuclear Gene Output Is Stoke ,Acadia Pharmaceuticals ,American Epilepsy Society ,Augmentation Of Nuclear Gene Output ,Nasdaq ,Stoke Therapeutics Inc ,Exchange Commission ,Company Annual Report On Form ,International Epilepsy Congress ,Third Quarter ,Dominant Optic Atrophy ,Year To Date Financial ,Collaboration Agreement ,Autosomal Dominant Optic Atrophy ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities ,Litigation Reform Act ,Annual Report ,Months Ended September ,Stoke Therapeutics Stock ,